http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-603868-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f5ef0e68a190669a8aea84eb19c83ee |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N29-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-10 |
| filingDate | 2011-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54aa0352ebf8a0cafd15c8c639e0f25a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad022bd3e488bb5792360bbe3d28cc76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_957f4a63d5e6f4c5ea0f63bf9e3ffb45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5790b38023b3e363e16c5ff1383ceebf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f07170c005e6f3c4c052d8a570fd6c4c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef63a57ded23459913fd6fb1999804c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a54ea54f7efc46b80b701d8056211d85 |
| publicationDate | 2014-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-603868-A |
| titleOfInvention | Novel spiroheterocyclic compounds as mglu5 antagonists |
| abstract | ABSTRACT - 603868 The disclosure relates to diazaspiro compounds having the general formula (I) wherein X is O or S; R1 is C, N, O or S; R1a is CH, CH2, N or NH; R2 is a bond, CH or CH2; m is 1, 2 or 3; n is 1 or 2; when n is 2 or m is 2 or 3, the ring containing R1 may be fused with a benzene ring; each ----- (dashed line) represents a single or double bond provided that one double bond extends from the carbon atom to which R3-C=C- is bonded and that no ring carbon atom bears two double bonds; and R3, R4 and R5 represent a wide range of substituents as defined in the specification. These compounds are selective for the metabotropic mGlu5 receptor. They, their solvates, hydrates, enantiomers, diastereomers, N-oxides and pharmaceutically acceptable salts, and pharmaceutical compositions containing them, can be used to treat diseases or disorders of the lower urinary tract, especially neuromuscular dysfunctions of the lower urinary tract. They may also be useful for the treatment of migraine; for the treatment of gastroesophageal reflux disease (GERD); for the treatment of anxiety disorder; for the treatment of abuse, substance dependence and substance withdrawal disorder; for the treatment of neuropathic pain disorder; and for the treatment of fragile X syndrome disorders. |
| priorityDate | 2010-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.